DABIGATRAN ETEXILATE FOR PREVENTION OF CARDIOEMBOLIC COMPLICATIONS IN NONVALVULAR ATRIAL FIBRILLATION: HOW TO DO THE INTERVENTION MORE EFFECTIVE AND SAFER

QR Code

DABIGATRAN ETEXILATE FOR PREVENTION OF CARDIOEMBOLIC COMPLICATIONS IN NONVALVULAR ATRIAL FIBRILLATION: HOW TO DO THE INTERVENTION MORE EFFECTIVE AND SAFER

Application of dabigatran etexilate for prevention of cardioembolic complications in nonvalvular atrial fibrillation is considered. Results of randomized clinical trials on efficacy and safety of dabigatran in various doses are discussed. Besides, a comparison of dabigatran and varfarin therapies is...

Full description

Saved in:

Bibliographic Details
Main Author:	I. S. Yavelov
Format:	Article
Language:	English
Published:	Столичная издательская компания 2016-01-01
Series:	Рациональная фармакотерапия в кардиологии
Subjects:	atrial fibrillation dabigatran randomized clinical trials
Online Access:	https://www.rpcardio.online/jour/article/view/991
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Dabigatran etexilate in patients with nonvalvular atrial fibrillation: benefits of application in certain clinical situations
by: E. I. Baranova, et al.
Published: (2019-11-01)

Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation
by: N. A. Novikova, et al.
Published: (2016-11-01)

DABIGATRAN ETEXILATE IN ELDERL Y PATIENTS WITH ATRIAL FIBRILLATION: WHATS NEW?
by: O. N. Tkacheva, et al.
Published: (2017-12-01)

PRACTICAL APPLICATION OF DABIGATRAN ETEXILATE FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION
by: E. D. Kosmacheva, et al.
Published: (2015-09-01)

HOW TO USE DABIGATRAN IN PATIENTS WITH ATRIAL FIBRILLATION
by: S. V. Moiseev
Published: (2015-12-01)

Reliability and safety of long-term dabigatran use in patients with atrial fibrillation
by: E. V. Serdechnaya, et al.
Published: (2013-04-01)

COMPARISON OF DIRECT COSTS OF DABIGATRAN AND WARFARIN THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION DURING PREPARATION FOR ELECTIVE CARDIOVERSION IN THE REAL CLINICAL PRACTICE
by: L. E. Kuvshinova, et al.
Published: (2015-09-01)

ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: NEW DATA AND NEW HORIZONS
by: M. Yu. Gilyarov, et al.
Published: (2016-01-01)

Rivaroxaban-Associated Hepatotoxicity: a Clinical Case and Literature Review
by: B. A. Tatarsky, et al.
Published: (2019-11-01)

PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: Yu. B. Belousov, et al.
Published: (2015-12-01)

NOVEL ANTICOAGULANTS FOR THROMBOEMBOLIC COMPLICATIONS PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION
by: D. A. Itkin, et al.
Published: (2015-02-01)

Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease
by: I. S. Daabul, et al.
Published: (2016-11-01)

Prevention of Cardioembolic Complications in Patients with Atrial Fibrillation: Efficacy and Safety of Left Atrial Appendage Isolation and Oral Anticoagulants
by: D. V. Pevzner, et al.
Published: (2022-09-01)

GENETIC PREDICTORS FOR CARDIOEMBOLIC STROKE IN PATIENTS WITH ATRIAL FIBRILLATION
by: V. A. Shulman, et al.
Published: (2014-10-01)

ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: A. V. Rudakova
Published: (2015-09-01)

New safety standards for anticoagulant therapy in the treatment of atrial fibrillation
by: E. I. Baranova
Published: (2018-11-01)

The CES1 Gene rs2244613 Minor Allele Impact on the Safety Profile of Dabigatran Etexilate: Meta-Analysis
by: S. P. Abdullaev, et al.
Published: (2020-11-01)

The Risk of Myocardial Infarction in Patients with Atrial Fibrillation Taking a Direct Thrombin Inhibitor: Myths and Reality
by: B. A. Tatarsky, et al.
Published: (2020-05-01)

ANTITHROMBOTIC THERAPY IN NONVALVULAR ATRIAL FIBRILLATION: PROBLEMS AND PROSPECTS
by: A. Y. Rychkov, et al.
Published: (2016-01-01)

Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice
by: A. A. Zarudsky, et al.
Published: (2020-03-01)

THE SELECTION PROBLEMS OF ANTITHROMBOTIC THERAPY IN NONVALVULAR ATRIAL FIBRILLATION WITH COMORBIDITIES
by: N. A. Koziolova, et al.
Published: (2015-08-01)

Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction
by: Z. D. Kobalava, et al.
Published: (2021-03-01)

ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: RECENT APPROACHES AND NEAR PERSPECTIVES
by: Ya. P. Dovgalevskiy, et al.
Published: (2016-01-01)

Pharmacokinetics and bioequivalence of the generic and original dabigatran etexilate after a single dose in healthy volunteers
by: V. B. Vasilyuk, et al.
Published: (2024-10-01)

Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation in Real Clinical Practice: in Appropriate Dose Reductions
by: V. A. Ionin, et al.
Published: (2021-05-01)

Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true
by: Yu. A. Bunin, et al.
Published: (2016-09-01)

Practical aspects of antithrombotic therapy in patients with atrial fibrillation and coronary artery disease
by: Zh. D. Kobalava, et al.
Published: (2021-10-01)

THE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN CLINICAL PRACTICE
by: S. V. Moiseev
Published: (2016-05-01)

ATRIAL FIBROSIS IS A MORPHOLOGICAL BASIS OF ATRIAL FIBRILLATION
by: O. M. Drapkina, et al.
Published: (2015-09-01)

Fibrosis biomarkers as predictors of left atrial appendage thrombosis in patients with nonvalvular atrial fibrillation
by: T. P. Gizatulina, et al.
Published: (2022-08-01)

Predictors of Thrombus Dissolution in the Left Atrial Appendage in Patients with Persistent Nonvalvular Atrial Fibrillation
by: E. S. Mazur, et al.
Published: (2022-03-01)

ENDOVASCULAR METHODS FOR CLOSURE OF THE LEFT ATRIAL APPENDAGE IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION FOR STROKE PREVENTION
by: R. V. Guchaev, et al.
Published: (2018-05-01)

Factors associated with inappropriate reduced doses of non-vita-min K antagonist oral anticoagulants in patients with atrial fibrillation
by: V. A. Ionin, et al.
Published: (2021-10-01)

ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT
by: E. L. Dolgova, et al.
Published: (2015-09-01)

Predictors of spontaneous echo contrast and left atrial appendage thrombosis in nonvalvular atrial fibrillation
by: N. Yu. Khorkova, et al.
Published: (2020-08-01)

Clinical performance of the atrial fibrillation in the Russian population depending on the antithrombotic therapy: findings from the GLORIA-AF registry phase 2
by: E. V. Shlyakhto, et al.
Published: (2020-12-01)

ANTICOAGULANT THERAPY FOR CHRONIC KIDNEY DISEASE AND ATRIAL FIBRILLATION: THE AXIS OF ROTATION BETWEEN THE POLES OF RISK
by: Z. D. Kobalava, et al.
Published: (2018-06-01)

Thromboembolic risk factors and predictors of left atrial appendage thrombosis in Far North patients with nonvalvular atrial fibrillation
by: N. Yu. Khorkova, et al.
Published: (2021-11-01)

Novel scale for predicting thrombosis of the left atrium and its appendage before catheter ablation or cardioversion in patients with nonvalvular atrial fibrillation or atrial flutter
by: I. A. Zaigraev, et al.
Published: (2023-06-01)

Optimal choice of prophylactic anticoagulant therapy for nonvalvular atrial fibrillation in the context of COVID-19 pandemic
by: A. S. Polyakov, et al.
Published: (2021-09-01)